Expression And Clinical Significance Of FMNL2,Src And Cortactin In Gastric Adenocarcinoma

Objective: By means of screening 113 gastric adenocarcinoma tissues and 60 normal gastric tissues adjacent to cancer,check Formin-like2(FMNL2),Src and Cortactin,moreover,and integrate with clinical trials,so as to search out the correlation between them and clinicopathological suffers.Methods: We took advantage of immunohistochemical method(Elivision method),to rate the staining of FMNL2,Src and Cortactin proteins in 113 gastric adenocarcinoma tissues,furthermore,the results that we perform an experiment were arranged and analyzed by SPSS25.0 software.Results: The expression of FMNL2,Src and Cortactin in gastric adenocarcinoma is consequential,and they demonstrate positive dye.The percentage that express positive of FMNL2,Src and Cortactin protein in mass which come from stomach was 62.83%,74.34 and 68.14%,differ in 15%,23.34% and 30%(come from natural gastric musoca),which mainly pertinent to TNM staging,thoroughness of invasion,disintegration extent,lymph or other sites.In gastric adenocarcinoma,the expressions of FMNL2,Src and Cortactin were congruous.According to Kaplan-Meier survival analysis,in 113 cases of gastric adenocarcinoma,the general living time of sufferers with positive expression of FMNL2,Src and Cortactin protein was clearly shorter than that of patients with electronegative expression.COX multivariate survival analysis model was used to determine the factors affecting gastric adenocarcinoma.It can be concluded that FMNL2,Src and Cortactin as risk factors affected gastric adenocarcinoma.Conclusion:The contents of FMNL2,Src and Cortactin were higher in all tests.Expressed in gastric adenocarcinoma,which indicates that FMNL2,Src and Cortactin may lead to the occurrence of gastric adenocarcinoma and promote its development.The common test of FMNL2,Src and Cortactin protein may contribute to a certain non-practical reference functions,for making a definite diagnosis of gastric adenocarcinoma,development of new drugs for inhibiting tumor cell proliferation and biotherapeutic action point.